Holen Sie sich die Stockscreener-App
14.05
4.29%
-0.63
Handel nachbörslich:
13.89
-0.16
-1.14%
Schlusskurs vom Vortag:
$14.68
Offen:
$14.13
24-Stunden-Volumen:
1.83M
Relative Volume:
0.69
Marktkapitalisierung:
$2.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-3.6399
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
+7.58%
1M Leistung:
+5.80%
6M Leistung:
+101.29%
1J Leistung:
-56.85%
1-Tages-Spanne:
$13.75
$14.29
1-Wochen-Bereich:
$12.43
$15.22
52-Wochen-Spanne:
$6.36
$35.90
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.05 | 2.09B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (DYN) Sees Downgrade by Oppenheimer | DYN Stoc - GuruFocus
Dyne Therapeutics (DYN) Is Up 17.0% After Positive One-Year ACHIEVE Trial Data for Z-Basivarsen – Has The Bull Case Changed? - Yahoo Finance
Heatmap analysis for Dyne Therapeutics Inc. and competitorsJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - newser.com
Signal strength of Dyne Therapeutics Inc. stock in tech scannersMarket Volume Summary & Stock Portfolio Risk Management - newser.com
Will Dyne Therapeutics Inc. stock keep outperforming rivalsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
What moving averages say about Dyne Therapeutics Inc.2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Can Dyne Therapeutics Inc. stock hit analyst price targets2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Dyne Therapeutics (NASDAQ:DYN) - MarketBeat
What machine learning models say about Dyne Therapeutics Inc.2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Is Dyne Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Rallies & AI Driven Stock Reports - newser.com
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 - Seeking Alpha
Stocks With Rising Relative Price Strength: Dyne Therapeutics - Investor's Business Daily
Dyne Therapeutics Inc. (DYN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Trading Up 10.8%Here's Why - MarketBeat
Dyne Therapeutics rises on positive data from myotonic dystrophy trial - Seeking Alpha
Dyne Therapeutics (DYN) Reports Encouraging Phase 1/2 Trial Resu - GuruFocus
Dyne Therapeutics Reports Strength, Function Improvement From Myotonic Dystrophy Drug Candidate in Ongoing Early Phase Trial - MarketScreener
What drives Dyne Therapeutics Inc stock priceTechnical Pattern Recognition & Free Exceptional ROI Methods - earlytimes.in
Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - MarketScreener
Dyne Therapeutics reports positive one-year data for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7%Here's Why - MarketBeat
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics reports positive one-year data for DM1 treatment - Investing.com
Dyne Therapeutics Reports Significant One-Year Clinical Data for Zeleciment Basivarsen in Patients with Myotonic Dystrophy Type 1 - Quiver Quantitative
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Dyne Therapeutics Reports 1-Year Functional Gains at 6.8 mg/kg | DYN Stock News - Stock Titan
Applying big data sentiment scoring on Dyne Therapeutics Inc.2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Applying Elliott Wave Theory to Dyne Therapeutics Inc.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Technical signs of recovery in Dyne Therapeutics Inc.Quarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Using Python tools to backtest Dyne Therapeutics Inc. strategiesPortfolio Performance Summary & Fast Moving Trade Plans - newser.com
What risks investors should watch in Dyne Therapeutics Inc. stock2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
Dyne Therapeutics Inc. stock momentum explainedJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data - Insider Monkey
Dyne Therapeutics Elects Brian Posner to Board - The Globe and Mail
Dyne Therapeutics' Valuation Leaves No Room For Error (NASDAQ:DYN) - Seeking Alpha
How Dyne Therapeutics Inc. stock performs in high volatility markets2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
Does Dyne Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Will Dyne Therapeutics Inc. stock sustain high P E ratiosEarnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Dyne Therapeutics Appoints Brian Posner to its Board of Directors - GlobeNewswire
Dyne Therapeutics appoints Brian Posner to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Appoints Brian Posner to Board of Directors - Quiver Quantitative
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '25 |
Sale |
13.27 |
894 |
11,863 |
95,017 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 05 '25 |
Sale |
13.41 |
144 |
1,931 |
94,873 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '25 |
Sale |
13.27 |
3,552 |
47,135 |
89,263 |
| Kerr Douglas | Chief Medical Officer |
Sep 05 '25 |
Sale |
13.41 |
873 |
11,707 |
88,390 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):